Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
In Vitro Diagnostics Cancer Approvals

Foundation Medicine Obtains FDA Approval For Non Small Cell Lung Cancer Companion Diagnostic

Executive Summary

Foundation Medicine and Novartis’ commercial partnership has achieved another success as Foudation’s Liquid CDx is approved.

You may also be interested in...



FoundationOne Nabs US FDA Approval As Companion Diagnostic For Rare Cancers

The approval is the 25th indication for the diagnostic, but the first for any companion diagnostic to Roche’s Rozlytrek. 

Orange County Entrepreneur Banks On Data-Based Approach To Detect, Treat Diseases

IV BioHoldings CEO Marty Keiser connects data, technology, capital and people to create start-ups focusing on liquid biopsy programs.

Guardant Health Launches New Firsts: Blood Test To Track Patient’s Response To Immunotherapy, Tissue-Based Test

Guardant’s launch of a new test to track patient’s response to immunotherapy or targeted drugs and new pan-cancer tissue test, brings it closer to “one-stop-shop” in cancer care continuum.

Table

View full table

Related Content

Medtech Insight
Scrip

Topics

Related Companies

Tags:
In Vitro Diagnostics Cancer Approvals
Latest Headlines

News We’re Watching – LivaNova And Medtronic Recalls; Approvals For Abbott And Guardant; Pediatric Device Grants

Legal Expert Weighs In On New US Mandate To Diversify Clinical Trials

Global Medtech Guidance Tracker: January 2023

UK Medtech Strategy Promises To Use Innovation Effectively And Build Resilience

See All
UsernamePublicRestriction

Register

MT144226

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By